Design for Recoverability, Not Just Speed, in Genomics Automation
In high throughput clinical genomics, we celebrate cycle times and samples per day. The metric I care about more is recoverability. When a liquid handler hiccups mid library prep or a thermocycler throws a temperature fault, can you contain the failure to a few wells and restart the run in minutes without compromising traceability? In a CLIA/CAP lab, that saves more patient reports than shaving 2 minutes from a protocol.
What has worked for us: smaller independent batches with in line QC gates; idempotent steps that are safe to re run; plate map snapshots and reagent lot capture at every checkpoint; explicit pause and resume states in the LIMS to rebuild deck state. We added dry run simulators to catch deck conflicts and made error handling consistent across Hamilton and Tecan so techs get the same plain language prompts and recovery scripts.
The result was fewer full plate write offs and faster MTTR when things go sideways, which increased true throughput more than a speed tweak. How do you quantify the ROI of recoverability, and what patterns make your NGS workflows restartable without risking contamination or data drift?
We quantify it as recoverable yield and effective throughput: samples/day × (1 − full‑plate‑writeoff‑rate) plus MTTR and reagent/labor avoided per incident; shifting to 8 - 16 sample micro‑batches with atomic checkpoints, plate sealers, strict pre/post‑PCR segregation, and idempotent SPRI/thermocycle steps cut our writeoffs by ~60% and paid back the engineering in under 3 months. A pattern that helped was a two‑phase commit in the LIMS (reserve indexes and lots, simulate deck, then commit on barcode scan and plate snapshot) paired with standardized recovery scripts that rebuild state and enforce clean‑tip, re‑seal, and environmental QC before resume to prevent contamination and drift.